The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. - Wikidata - wikimedia - TriplyDB

The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.

The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.

http://www.wikidata.org/entity/Q30484934

about

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma Anaplastic lymphoma kinase: signalling in development and disease The role of the ALK receptor in cancer biology Approaches of targeting Rho GTPases in cancer drug discovery Vav family exchange factors: an integrated regulatory and functional view Human synthetic lethal inference as potential anti-cancer target gene detection Vav1 fine tunes p53 control of apoptosis versus proliferation in breast cancer Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice.New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008.The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma.Brentuximab vedotin in anaplastic large cell lymphoma.β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.Targeting activated Rho proteins: a new approach for treatment of HPV and other virus-related cancers?Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.

P2860

Q21129306-CCC7E52E-B760-409F-B9D6-9F19BE36D96D Q24312329-84386BFE-1E78-452A-83D5-10125A5A4077 Q26738384-806CB8CF-2F3F-452F-8E79-C7BFF263B407 Q26851300-2F8BCD7F-5F06-4224-80AE-34032AEB07E1 Q27026905-AFC5F51F-A4ED-440F-93AB-82C37154464D Q33518904-4EDA29C7-6CFB-4C49-AA59-84A58A78B7E6 Q34559351-445786D5-73CC-4EA6-8FAC-427A3798D0DD Q35664324-6F43D542-1F4B-4023-B2B1-FF8562E24509 Q36145016-FA3F5902-13F7-47AC-89C3-CDF0147F6D81 Q36557133-D040C23F-D3A1-46D8-8497-58D5000AD9BD Q36675069-F3FD44DC-235E-45F3-B6A0-5DAAFF9CBD89 Q37269044-154840CA-E38F-4E0E-9C8D-193424F76C73 Q37981983-74BCF196-A0CA-481A-96B3-024C31482235 Q38106810-1901B975-B5B0-4726-903F-01794B45C470 Q38742822-54898ED8-3E8D-470F-8B58-ABEB38793115 Q39636512-6BD6D787-D4E0-4F2E-BEFC-C92B03C8935D Q39640523-F4BA4330-2C15-4579-ABCC-7161BE9FF8E9 Q41004137-19F952E2-ACD2-412D-A9AD-14E926283904 Q42052786-27E862CD-35C1-4C16-AC3D-071FE852D117 Q45364512-E3066C74-F523-4135-A255-3F588192F128 Q47777234-9C3EAA80-020F-4F10-BC4E-7F48504972DA Q49186472-AF8D4932-CD57-4C44-8CA4-A9792D5BC9EF

P2860

The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.

http://www.wikidata.org/entity/Q30484934

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

The anaplastic lymphoma kinase ...... homa through Cdc42 activation.

@ast

The anaplastic lymphoma kinase ...... homa through Cdc42 activation.

@en

type

label

The anaplastic lymphoma kinase ...... homa through Cdc42 activation.

@ast

The anaplastic lymphoma kinase ...... homa through Cdc42 activation.

@en

prefLabel

The anaplastic lymphoma kinase ...... homa through Cdc42 activation.

@ast

The anaplastic lymphoma kinase ...... homa through Cdc42 activation.

@en

P1433

Q30484934-EB42690C-CC1A-445B-98B4-4F45D5924DCC

P1476

Q30484934-FA510D96-C78C-4536-B149-446FB9899A78

P2093

Q30484934-21FD0DA3-B646-49CB-95D9-D88163F9479F

Q30484934-3D746B57-5166-49AC-B1F6-675D863C88C3

Q30484934-811EAF78-21C9-4EF1-A053-52032B8F3876

Q30484934-86C3932A-60AA-47D0-9684-2A76883B6FF3

Q30484934-A0748C9B-3D5D-47D7-998E-40DDCC535BA6

Q30484934-BD7A4371-AD4B-4FAD-99D6-56B6D817EF19

Q30484934-C79BFE9B-54C3-486B-AE5D-377EF8BA085A

Q30484934-FDA3719A-F723-4A15-B375-E4130F12F7F2

P2860

Q30484934-04B6274A-680A-4500-A3EB-33D1E625DC33

Q30484934-0831D772-3CAB-4906-A5A6-31EA81ADA6B7

Q30484934-09C59B87-303A-4C50-83F4-C5E6BB310A91

Q30484934-0F6226FF-EC8C-452C-B048-3899E88B9A32

Q30484934-14480ECD-4F93-4669-9818-39AC2E3F9DB4

Q30484934-30E5DC95-D806-48E9-9E76-991BBE9189EF

Q30484934-3FAFBD34-E614-435A-9F91-B8534DE6C1CD

Q30484934-424F3E22-E844-4933-9684-BCEEDB99286C

Q30484934-4D3C2559-7CFB-445D-BC2F-803B2BFC5FD8

Q30484934-52E63CB5-8307-42D8-A8E4-30B30E963137

P304

Q30484934-7A31EFB9-043A-48B0-89B7-974FF57657CA

P31

Q30484934-B0C7B8B6-313B-4416-9CF8-8A389210E7B0

P356

Q30484934-D7C99ABD-E854-4130-9DD6-C205E45A4631

P407

Q30484934-81EF50AB-43A9-4ED8-8D5E-E43DD78786EE

P433

Q30484934-425817BE-E7E8-441A-B10F-EA7D7597E7E3

P478

Q30484934-65EFD7F2-026B-4B89-BA38-4962E31F6623

P50

Q30484934-4BF87E41-7D28-454A-B39E-9ADB624A8F26

Q30484934-703804CE-0DD5-4818-9161-53E93733B3CC

Q30484934-B69FCCF2-6679-4CCE-A1AD-2BD99F755BB8

Q30484934-C2DB977B-2CCC-4E30-8FA3-EBA0C42ED603

Q30484934-D50AB037-46EF-461D-8898-9AE0199E56A5

Q30484934-F3568B42-1EAD-4CB2-8BE3-B3AE894B3D3A

P577

Q30484934-BF3E21A6-C6EA-4058-9527-0BADCDB7B962

P698

Q30484934-7BCEFF4D-6861-4427-BEC7-E2DD3B57D534

P932

Q30484934-CCC4C8C8-461F-41F1-9700-3C371A284553

P356

0008-5472.CAN-08-2568

P1433

Cancer Research

P1476

The anaplastic lymphoma kinase ...... homa through Cdc42 activation.

@en

P2093

Andrea D Manazza

http://www.w3.org/2001/XMLSchema#string

Carlotta Costa

http://www.w3.org/2001/XMLSchema#string

Chiara Ambrogio

http://www.w3.org/2001/XMLSchema#string

Cinzia Martinengo

http://www.w3.org/2001/XMLSchema#string

Claudia Voena

http://www.w3.org/2001/XMLSchema#string

Giorgio Inghirami

http://www.w3.org/2001/XMLSchema#string

Roberto Chiarle

http://www.w3.org/2001/XMLSchema#string

Tomas Kirchhausen

http://www.w3.org/2001/XMLSchema#string

P2860

p130Cas mediates the transforming properties of the anaplastic lymphoma kinase

Crucial structural role for the PH and C1 domains of the Vav1 exchange factor

Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics

Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation

Biology of the p21-activated kinases

P304

8899-8907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-08-2568

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Chiarle

Cinzia Martinengo

Giorgio Inghirami

Chiara Ambrogio

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18974134

http://www.w3.org/2001/XMLSchema#string

P932

2596920

http://www.w3.org/2001/XMLSchema#string